Revisiting the role of eotaxin-1/CCL11 in psychiatric disorders
dc.contributor.author | Teixeira, Antônio Lúcio | pt_BR |
dc.contributor.author | Gama, Clarissa Severino | pt_BR |
dc.contributor.author | Rocha, Natalia Pessoa | pt_BR |
dc.contributor.author | Teixeira, Mauro Martins | pt_BR |
dc.date.accessioned | 2018-09-18T02:30:01Z | pt_BR |
dc.date.issued | 2018 | pt_BR |
dc.identifier.issn | 1664-0640 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/182092 | pt_BR |
dc.description.abstract | Eotaxin-1/CCL11 is a chemokine originally implicated in the selective recruitment of eosinophils into inflammatory sites during allergic reactions, being thoroughly investigated in asthma, allergic rhinitis, and other eosinophil-related conditions. Eotaxin-1/CCL11 is also involved with a skewed immune response toward a type-2 (Th2) profile. In addition to its role in immune response, recent studies have shown that eotaxin-1/CCL11 is associated with aging, neurogenesis and neurodegeneration, being able to influence neural progenitor cells, and microglia. Increased circulating levels of eotaxin-1/CCL11 have been described in major psychiatric disorders (schizophrenia, bipolar disorder, major depression), sometimes correlating with the severity of psychopathological and cognitive parameters. As similar findings have been reported in neurodegenerative conditions such as Alzheimer’s disease, it has been hypothesized that mechanisms involving eotaxin-1/CCL11 signaling may underlie the “accelerated aging” profile commonly linked to psychiatric disorders. Future studies must determine whether eotaxin-1/CCL11 can be regarded as a prognostic biomarker and/or as therapeutic target for resistant/progressive cases. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Frontiers in psychiatry. Lausanne. Vol. 9 (June 2018), 241, 6 p. | pt_BR |
dc.rights | Open Access | en |
dc.subject | Eotaxin-1 | en |
dc.subject | Esquizofrenia | pt_BR |
dc.subject | CCL11 | en |
dc.subject | Transtorno bipolar | pt_BR |
dc.subject | schizophrenia | en |
dc.subject | Envelhecimento | pt_BR |
dc.subject | bipolar disorder | en |
dc.subject | Doença de Alzheimer | pt_BR |
dc.subject | Quimiocina CCL11 | pt_BR |
dc.subject | depression | en |
dc.subject | aging | en |
dc.subject | Alzheimer’s disease | en |
dc.title | Revisiting the role of eotaxin-1/CCL11 in psychiatric disorders | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001073428 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Files in this item
This item is licensed under a Creative Commons License
-
Journal Articles (39706)Health Sciences (10620)